Anthropic establishes biology lab for Claude’s drug R&D experiments

Anthropic has quietly established a dedicated biology lab to advance its AI drug program. By integrating Claude into drug R&D experiments, the company aims to revolutionize treatments for rare diseases. This strategic move is expected to accelerate the discovery process and potentially lower overall costs. The initiative marks a significant expansion of Anthropic's capabilities, leveraging artificial intelligence to drive innovation within the pharmaceutical sector and enhance the efficiency of medical research and development.